Experiences in the Treatment of North American Blastomycosis with 2-Hydroxystilbamidine

Publisher Website
Google Scholar
Abstract
Of 26 patients, 23 were preferentially treated with 2-hydroxystilbamidine with only 2 therapeutic failures. In contrast to classical therapy with stilbamidine and amphotericin B, there were no instances of major toxic reaction. Minor febrile reactions and nausea with vomiting were a occasional complications but did not require interruption of therapy. The average amount of 2-hydroxystilbamidine used was 8.67 g given usually as 225 mg daily intravenously. Multiple courses of therapy were infrequent and only in one instance of pulmonary cavitation was resectional therapy resorted to. Adequate follow-up was obtained in all instances and not one of the 21 successfully treated patients suffered an infectious relapse. Only 2 cases were followed for less than 12 months; the remaining 19 remained well for at least 2 years and 9 of these for longer than 4 years. The 2 failures with 2-hydroxystilbamidine occurred in patients with extensive infection. One was a 9-year-old child who was critically ill when first seen and later died. The other patient had relapsed after several courses of classical stilbamidine therapy but clinical arrest was eventually achieved with amphotericin B.

This publication has 6 references indexed in Scilit: